Question: In postmenopausal women with osteoporosis is once monthly oral ibandronate (150 mg) therapy preferred to once weekly oral bisphosphonate therapy

J Okla State Med Assoc. 2012 Mar;105(3):89-90.
No abstract available

MeSH terms

  • Bone Density Conservation Agents / administration & dosage
  • Bone Density Conservation Agents / therapeutic use*
  • Diphosphonates / administration & dosage
  • Diphosphonates / therapeutic use*
  • Drug Administration Schedule
  • Female
  • Humans
  • Ibandronic Acid
  • Osteoporosis, Postmenopausal / prevention & control*
  • Patient Preference
  • Randomized Controlled Trials as Topic

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Ibandronic Acid